Our New PI, Dr Sarah Routledge
Sarah joined Gifford Bioscience in 2021, following 10 years of post-doctoral research at the Universities of Birmingham, Cambridge, Warwick and Aston. She was appointed a Principal Investigator in April 2023. “It is incredibly...
An Introduction To Gifford Bioscience
Watch our Corporate Video to find out more about who we are and the assays that we do. An introduction to our company, our scientists in action, an overview of the various assay techniques. Video Link - Click Here...
ELRIG 22 Poster Presentation
Gifford Bioscience will be attending ELRIG Drug Discovery in London on the 4th-5th October 2022. Dr Maria Azam; Dr Sarah Routledge and Dr Sian Stockton will be presenting our poster “Avidity vs Affinity: A Common Biosensor...
SfN – We’re Exhibiting
We are exhibiting at the Society for Neuroscience conference 2022 in San Diego, 12th to 16th November. Come and visit us at booth number 2608 for a chat about radioligand binding assays, SPR, autoradiography and, of course, to...
Birmingham’s New Life Sciences Park
A world-class, new life science park is being built here in Birmingham, opening in 2023, and we are planning to be part of the story. We are delighted to have secured space in the flagship building at the Precision Health...
We Are Hiring
We are looking for a Senior Scientist / Scientist to join our close knit, friendly team here in Birmingham, UK. If you have in-depth experience in receptor pharmacology, find out more about the position on our Careers...
Business Continuity
Our laboratory facilities remain operational under the current national restrictions, with a suite of risk mitigation measures in place. Scientists may be working from home, however, when analyzing data or writing...
“SPR Evaluation of Potential Anti-COVID-19 Therapies” poster presentation at ELRIG Drug Discovery Digital 2020
ELRIG Drug Discovery Digital 2020 is starting this week, and Dr Clare Box and Dr Kevin Thompson are going to be there, virtually, to present their research evaluating novel COVID-19 therapies through the use of SPR. ELRIG Drug...
Small Molecules, Binding to AT2 Site on ACE2, Unlikely to Prevent COVID-19 Spike Protein Binding
Angiotensin II and SARS-CoV-2 ‘spike’ protein bind to independent sites on angiotensin converting enzyme 2. We used the Biacore Surface Plasmon Resonance (SPR) technique to show that the peptide angiotensin II (AT2, that is...
COVID-19 Decoy: ACE2 in Solution “Decoys” Spike Protein, Inhibiting Binding to Surface Bound ACE2
Using the Biacore Surface Plasmon Resonance (SPR) technique, we have quantified the kinetic receptor binding parameters for COVID-19 / SARS-CoV-2 ‘spike’ protein to the trans-membrane receptor Angiotensin Converting Enzyme 2...
Contact Us

Copyright © 2023 Gifford Bioscience Limited
Privacy Policy